Australian hip fractures on the rise, despite incidence drop
This article was originally published in Clinica
Executive Summary
Australia has seen a significant fall in the overall incidence rate of osteoporotic hip fractures over the last decade, but the expanding greying population is still pushing the actual number of cases up, according to a report released today by the Australian Institute of Health and Welfare (AIHW).
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.